|  | Death | Recurrence |
---|
 | Crude HR | adjusted HR a | Crude HR | adjusted HR b |
---|
Beclin-1 | Negative | 1.0 | 1.0 | 1.0 | 1.0 |
 | Positive |
2.39 (1.09–5.24)
|
2.51 (1.05–5.99)
|
2.27 (1.09–4.75)
| 1.85 (0.85–4.06) |
ARID1A | Negative | 1.0 | 1.0 | 1.0 | 1.0 |
 | Positive | 1.59 (0.95–2.66) |
1.95 (1.09–3.47)
|
1.71 (1.06–2.78)
|
2.08 (1.23–3.51)
|
- Bold indicates statistical significance, p < 0.05
- amodel controlled for age, GGT before surgery, ALP before surgery, CEA before surgery, number of lesions, tumor size, lymphatic metastasis, nerve invasion, involving extrahepatic tissue, mucus, tumor generalization, TNM stage.
- b model controlled for GGT before surgery, ALP before surgery, CEA before surgery, number of lesions, tumor size, lymphatic metastasis, involving extrahepatic tissue, necrosis, mucus, TNM stage.